{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:04Z","timestamp":1793824624754,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1053\/j.gastro.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T19:23:52Z","timestamp":1749497032000},"page":"1268-1281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis"],"prefix":"10.1053","volume":"169","author":[{"given":"Cho-Hung","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aunchalee","family":"Jaroenlapnopparat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena Cakir","family":"Colak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nutchapon","family":"Xanthavanij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsu-Hsien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Ya","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Wei","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan Ping","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Han","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2025.06.003_bib1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.14309\/ajg.0000000000002519","article-title":"Effects of GLP-1 and other gut hormone receptors on the gastrointestinal tract and implications in clinical practice","volume":"119","author":"Camilleri","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.06.003_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.gastro.2025.06.003_bib3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2025.06.003_bib5","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"10.1053\/j.gastro.2025.06.003_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.06.003_bib8","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","article-title":"Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian Cohort Study","volume":"22","author":"Ueda","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.06.003_bib9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1053\/j.gastro.2018.11.017","article-title":"Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery","volume":"156","author":"Albaugh","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2025.06.003_bib10","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1210\/en.2015-1321","article-title":"Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors","volume":"156","author":"Brighton","year":"2015","journal-title":"Endocrinology"},{"key":"10.1053\/j.gastro.2025.06.003_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/phar.2688","article-title":"Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: a nationwide cohort study","volume":"42","author":"Dong","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.gastro.2025.06.003_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1053\/j.gastro.2025.06.003_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2025.06.003_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.200611-1717OC","article-title":"Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies","volume":"175","author":"Beuther","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib15","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/thx.2007.086843","article-title":"Obesity and the lung: 2. Obesity and sleep-disordered breathing","volume":"63","author":"Crummy","year":"2008","journal-title":"Thorax"},{"key":"10.1053\/j.gastro.2025.06.003_bib16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1164\/rccm.200904-0530OC","article-title":"Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance","volume":"180","author":"Ora","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib17","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1378\/chest.14-1308","article-title":"Overweight and obesity are risk factors for COPD misdiagnosis and overtreatment","volume":"146","author":"Franssen","year":"2014","journal-title":"Chest"},{"key":"10.1053\/j.gastro.2025.06.003_bib18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17476348.2018.1506331","article-title":"The effect of obesity on lung function","volume":"12","author":"Dixon","year":"2018","journal-title":"Expert Rev Respir Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib19","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1464-5491.2010.03073.x","article-title":"Systematic review of the association between lung function and type 2 diabetes mellitus","volume":"27","author":"Klein","year":"2010","journal-title":"Diabet Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1900\/RDS.2019.15.1","article-title":"Diabetes and lung disease: a neglected relationship","volume":"15","author":"Khateeb","year":"2019","journal-title":"Rev Diabet Stud"},{"key":"10.1053\/j.gastro.2025.06.003_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00011-018-1191-2","article-title":"A review of inflammatory mechanism in airway diseases","volume":"68","author":"Aghasafari","year":"2019","journal-title":"Inflamm Res"},{"key":"10.1053\/j.gastro.2025.06.003_bib22","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib24","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1111\/dom.15263","article-title":"Efficacy and safety of adding once-weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD-CHN3): a randomized, double-blind, placebo-controlled, phase III trial","volume":"25","author":"Wang","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2025.06.003_bib25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib26","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib27","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib29","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Fr\u00edas","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.06.003_bib30","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib32","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2337\/dc12-2006","article-title":"Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)","volume":"36","author":"Ahr\u00e9n","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib33","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"J Diabetes Complications"},{"key":"10.1053\/j.gastro.2025.06.003_bib34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib35","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/dc17-2381","article-title":"A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin","volume":"41","author":"Lingvay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib36","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/dom.13978","article-title":"Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Blonde","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.gastro.2025.06.003_bib37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib38","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamainternmed.2016.1540","article-title":"Effect of adding liraglutide vs placebo to a high-dose lnsulin regimen in patients with type 2 diabetes: a randomized clinical trial","volume":"176","author":"Vanderheiden","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib39","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.06.003_bib41","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib42","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib44","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","article-title":"Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, phase IIIa, randomised trial","volume":"67","author":"Wang","year":"2024","journal-title":"Diabetologia"},{"key":"10.1053\/j.gastro.2025.06.003_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.06.003_bib46","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.06.003_bib48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib49","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.gastro.2025.06.003_bib50","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib52","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.06.003_bib53","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2025.06.003_bib54","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"10.1053\/j.gastro.2025.06.003_bib55","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.06.003_bib56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib57","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1053\/j.gastro.2025.06.003_bib58","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1053\/j.gastro.2025.06.003_bib59","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib60","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib61","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.06.003_bib62","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.06.003_bib63","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.06.003_bib64","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib66","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabet Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib67","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2025.06.003_bib70","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib71","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.06.003_bib72","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2025.06.003_bib73","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S2213-8587(24)00377-2","article-title":"Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"13","author":"Kadowaki","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.gastro.2025.06.003_bib74","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.06.003_bib75","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib76","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.06.003_bib77","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/sim.791","article-title":"On tests of the overall treatment effect in meta-analysis with normally distributed responses","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib78","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib79","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1053\/j.gastro.2025.06.003_bib80","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2025.06.003_bib81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2307\/2982993","article-title":"Publication bias: a problem in interpreting medical data","volume":"151","author":"Begg","year":"1988","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"10.1053\/j.gastro.2025.06.003_bib82","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"10.1053\/j.gastro.2025.06.003_bib83","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamainternmed.2022.3810","article-title":"Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the US Food and Drug Administration","volume":"182","author":"Woronow","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib84","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00042737-200012120-00015","article-title":"Gallstones in obesity and weight loss","volume":"12","author":"Erlinger","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2025.06.003_bib85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1381\/096089203322190862","article-title":"Impact of rapid weight reduction on risk of cholelithiasis after bariatric surgery","volume":"13","author":"Igl\u00e9zias Brand\u00e3o de Oliveira","year":"2003","journal-title":"Obes Surg"},{"key":"10.1053\/j.gastro.2025.06.003_bib86","first-page":"1000","article-title":"Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity","volume":"86","author":"Shiffman","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2025.06.003_bib87","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/0003-4819-133-6-200009190-00014","article-title":"Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues","volume":"133","author":"Temple","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2025.06.003_bib88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the national institutes of health all of us cohort","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1053\/j.gastro.2025.06.003_bib89","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes","volume":"111","author":"Faillie","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2025.06.003_bib90","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/gutjnl-2023-329651","article-title":"Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study","volume":"73","author":"Liu","year":"2024","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2025.06.003_bib91","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0001037628.17155.33","article-title":"S2065 GLP-1 Agonist use is associated with lower incidence of GERD, lower use of PPIs and does not complicate GERD in patients with obesity who undergo sleeve gastrectomy: a national database analysis","volume":"119","author":"Narvaez","year":"2024","journal-title":"Am J Gastroenterol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525008455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508525008455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T23:11:45Z","timestamp":1761433905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508525008455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0016508525008455"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2025.06.003","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute.","name":"copyright","label":"Copyright"}]}}